Arena Pharmaceuticals — Investor Presentation (January 2021)
21 slides from Arena Pharmaceuticals's investor presentation, Jan 11, 2021
Slide 1: January 2021 Corporate Presentation
JANUARY 2021 • NASDAQ: ARNA Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-cla
Slide 3: Transforming into a Global Business
TRANSFORMING INTO A GLOBAL BUSINESs 3
Slide 4: Our Science: A Strong Foundation for Continuous Pipeline Growth
Our Science A STRONG FOUNDATION FOR CONTINUOUS PIPELINE GROWTH LIFE CYCLE MANAGEMENT PC 4
Slide 5: Diversified Portfolio
Diversified Portfolio STRONG IP + UNENCUMBERED ASSETS* + ACTIVE DISCOVERY ENGINE *Unencumbered refers to olorinab, APD418, Temanogrel. Etrasimod is unencumbered in all areas of the world with the exception of China and South Korea where we’ve established a partnership with Everest Medicines 5
Slide 6: Coronary Microvascular Obstruction: A Serious Condition with High Unmet Need
40-60% of high-risk ACS patients (480K in US) fail to achieve full myocardial reperfusion Insult occurring during percutaneous coronary intervention (PCI) results in activation of platelets and release of serotonin (5-HT) Release of 5-HT mediates platelet aggregation and vasoconstriction leading to
Slide 7: Temanogrel Mechanism of Action
temanogrel Mechanism of Action TEMANOGREL: PERIPHERALLY ACTING 5-HT2A INVERSE AGONIST ADDRESSING MEDIATORS OF cMVO Platelets Contain Serotonin (5-HT) 7 Golino et al 1995 NEJM ; Kleinbongard, et al. Circ Res 2009;108:344-352; Kleinbongard, et al. Am J Physiol Heart Circ Physiol 2013;305: H1222–H1229;
Slide 8: Proof of Mechanism With 5-HT2A Antagonist
Higher levels of coronary sinus 5-HT associated with increased vasoconstriction* IV Ketanserin (KET) reduces vasoconstriction in distal vessels post-angioplasty *post-angioplasty (elective) for left anterior descending or left circumflex coronary artery stenosis Golino et al. N Engl J Med. 1994;330:
Slide 9: cMVO Market Opportunity
cmvo market opportunity 9 Sources: 1Masoudi FA et al. 2016 Report From 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol 2017;69:1427–50; Limalanathan S. Myocardial Salvage is Reduced in Primary PCI-Treated STEMI Patients with Microvascular Obstruction, Demonstrated by Early and Late
Slide 10: Temanogrel Development Program
Temanogrel Development Program CAPITALIZING ON PROGRESS AND FAST-TRACK DESIGNATION IV Formulation: 1 completed Phase 1 study Oral Formulation: 4 completed Phase 1 studies Phase 2a: In Elective NSTEMI PCI Single IV bolus - dose selection for Phase 2 (791-202) study Single + repeated doses (with and w
Slide 11: Diversified Portfolio
Diversified Portfolio STRONG IP + UNENCUMBERED ASSETS* + ACTIVE DISCOVERY ENGINE 11 *Unencumbered refers to olorinab, APD418, Temanogrel. Etrasimod is unencumbered in all areas of the world with the exception of China and South Korea where we’ve established a partnership with Everest Medicines
Slide 12: Etrasimod Launch Readiness
Etrasimod Launch Readiness MARKET INSIGHTS Generate key market insights to inform clinical and payer evidence CLINICAL VALUE Enhanced formulation, executing peri-approval studies SCIENTIFIC EXCHANGE Data generation, medical communications, MSLs, advisory boards ENSURE ACCESS Harness AI to create pre
Slide 13: Arena's Global Footprint
GLOBAL PRESENCE Arena’s Global Footprint *Etrasimod partnered in China and South Korea with Everest Medicines INTERNATIONAL 30 R&D 25 Customer Facing 40 COUNTRIES 500 Clinical Trial Sites US 200 R&D 30 Customer Facing SAN DIEGO BOSTON ZUG INFRASTRUCTIVE FOR ANTICIPATED LAUNCH & PRODUCTIVE INVESTMENT
Slide 14: Ulcerative Colitis Market Opportunity
Ulcerative colitis (uc) Market Opportunity GLOBAL UC ADVANCED LINE MARKET EXPECTED TO GROW IN ALL 7 MAJOR MARKETS Source: 1. DRG UC and CD Disease Landscape & Forecast 2020; 2. Crohn's and Colitis Foundation About the Epidemiology of IBD UC Diagnosed Prevalence (7MM) ONLY 2 OF 5 UC PATIENTS ARE ON A
Slide 15: Atopic Dermatitis Market Opportunity
Atopic dermatitis (AD) Market Opportunity AD MARKET EXPECTED TO GROW SUBSTANTIALLY IN ALL 7 MAJOR MARKETS 15 <5% OF MODERATE-SEVERE AD PATIENTS ARE TREATED WITH DUPILUMAB AD Market Size Sales (USD, millions) $2.1B $24.2B 1. Source: DRG AD Disease Landscape & Forecast 2019’ *Note: based on SCORAD (ch
Slide 16: Clinical Development Expertise
Clinical Development Expertise Leadership experience BREADTH AND DEPTH OF EXPERIENCE: FROM DRUG DEVELOPMENT TO LAUNCH 30 Phase 3 Programs Regulatory Experience 50 INDs 17 NDAs Commercial Successes 17 Launches 8 Top-Ten Drugs M&A and Licensing Collective Transaction Experience Exceeding $30 Billion 1
Slide 17: High-Performance Culture
High-Performance Culture BUILDING A SUSTAINABLE BUSINESS OUR COMMITMENT TO SOCIAL RESPONSIBILITY 17
Slide 18: Catalyst Horizon
Catalyst Horizon* 18 *All Timelines and Catalysts are Subject to COVID-19 Impact **Dependent on regulatory interactions PHASE 3 PHASE 2 Etrasimod AA Ph 2 Data Etrasimod ELEVATE UC 52 Ph 3 Data APD418 Ph 2a Data Etrasimod CULTIVATE (CD) Ph 2 Dose-Ranging Data Olorinab CAPTIVATE (IBS Pain) Ph 2b Data
Slide 19: Arena by the Numbers
Arena by the numbers 4 CLINICAL STAGE ASSETS* 8 DISEASE AREAS 2 PH 3 5 PH 2 1 IND EXPECTED EACH YEAR THROUGH [2022] 7 DATA READOUTS: 2 PRECLINICAL ASSETS 3 THERAPEUTIC AREAS *Etrasimod, olorinab, APD418, temanogrel
Slide 20: Toward a Bold Future
TOWARD a bold future Pipeline Growth • Commercialization Excellence Leadership & Culture • Long-Term Value 20
Slide 21: Arena Pharmaceuticals
/\RI-NA PHARMACEUTICALS Care Mow. Pippen JANUARY 2
Arena Pharmaceuticals — Investor Presentation (January 2021) on 6ix